A high hsCRP value predicts a clearly elevated long-term risk of serious cardiovascular events, even more strongly than LDL cholesterol or Lp(a) in the studied cohort. These are robust associations observed over decades and across large populations, with additional mechanistic support via IL-6. In practical terms, this means a raised hsCRP should never be dismissed as a side issue: it is an independent reason to discuss with your doctor whether your total cardiovascular risk has been fully mapped and treated.
A high hsCRP value is a serious warning signal for your heart. In a long-running study of nearly 28,000 initially healthy women followed for 30 years, women with the highest hsCRP values at baseline had a 70% higher chance of a first serious cardiovascular event (heart attack, stroke, angioplasty or bypass surgery, or death from cardiovascular disease) than women with the lowest values. Notably, hsCRP was an even slightly stronger predictor than LDL cholesterol or Lp(a), two blood markers that most people know as risk factors.
CRP is not simply a marker that tracks alongside cholesterol. Three large cohort studies (including the UK Biobank) showed that Lp(a) and hsCRP raise risk through two entirely separate mechanisms: a high Lp(a) increases risk regardless of whether your CRP is low or high, and vice versa. You therefore cannot get an accurate picture of your cardiovascular risk by looking at cholesterol alone; inflammation is an independent factor.
CRP itself probably does not cause the damage, but is a measure of a deeper underlying inflammatory process. The substance that prompts the liver to produce CRP is called IL-6. Multiple studies and genetic research indicate that high IL-6 levels are themselves also directly associated with more cardiovascular disease: greater cardiovascular mortality, heart attacks, strokes and heart failure. A raised CRP is therefore also a signal that this underlying inflammatory system is overactive.
A raised hsCRP also plays a role if you are already taking cholesterol-lowering medication. Even with optimal LDL reduction, cardiovascular risk remains, and inflammation is one of the most important explanations for that. Colchicine is currently the only drug approved by regulatory authorities that specifically targets this chronic low-grade inflammation. If your CRP remains high despite treated cholesterol, that is a signal to speak with your doctor about this 'residual risk'.
In the area of lifestyle, there is moderate evidence that a diet with a low glycaemic index or glycaemic load lowers CRP values. A meta-analysis of 29 randomised trials in people with type 1 or type 2 diabetes showed a statistically significant, though modest, reduction in CRP, alongside improvements in blood sugar, cholesterol and blood pressure. The researchers themselves rated the certainty of this evidence as 'moderate', so this is not a miracle cure, but a low-glycaemic eating pattern is a logical step if your CRP is elevated and you have diabetes.
All claims are based on five controlled sources: one large prospective cohort study with 30 years of follow-up (PMID 39216091), three large cohort studies summarised in one publication on Lp(a) and hsCRP (PMID 38353970), a narrative review on IL-6 (PMID 39589436), a review article on residual risk and colchicine (PMID 37845117), and a meta-analysis of 29 RCTs on a low-glycaemic diet in diabetes (PMID 34348965). The associative cohort studies do not demonstrate proven causality of CRP itself; IL-6 does have mechanistically and genetically supported indications of causality.